Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Tango Therapeutics Inc. — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $14.92 (market cap $7.03B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Norwegian Cruise Line Holdings Ltd is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 69 Days and Tango Therapeutics Inc. for 0 Days on average.
| NCLH | TNGX | |
|---|---|---|
Market Cap | $7.03B | $3.75B |
Volume | 12,698,429 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $32.90 |
52-Week Low | $14.12 | $7.50 |
Typical Hold Time | 69 Days | 0 Days |
Enterprise Value | $21.85B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norwegian Cruise Line Holdings (NCLH) trades at $14.87, down 3.13% today, with mixed technical signals showing neutral overall but bearish moving averages. The company demonstrates strong fundamental recovery with Q2 2026 EPS beating expectations at $0.48 versus $0.41, and maintains positive cash flow trends. Recent news highlights management's expectation for Q3 2026 results to exceed guidance, while facing yield pressure through 2027.
NCLH presents a compelling value opportunity with a low P/E of 9.28 and strong analyst consensus price target of $20.86 (40% upside), though elevated debt levels and Caribbean pricing pressure pose near-term risks. The stock's investment case hinges on continued operational execution and demand stabilization amid industry headwinds.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
